Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 3/2016

01-03-2016 | Original Article

An integrative transcriptomic analysis reveals p53 regulated miRNA, mRNA, and lncRNA networks in nasopharyngeal carcinoma

Published in: Tumor Biology | Issue 3/2016

Login to get access

Abstract

It has been reported that p53 dysfunction is closely related to the carcinogenesis of nasopharyngeal carcinoma (NPC). Recently, an increasing body of evidence has indicated that microRNAs (miRNAs) and long noncoding RNAs (lncRNAs) participate in p53-associated signaling pathways and, in addition to mRNAs, form a complex regulation network to promote tumor occurrence and progression. The aim of this study was to elucidate the p53-regulated miRNAs, mRNAs, and lncRNAs and their regulating networks in NPC. Firstly, we overexpressed p53 in the NPC cell line HNE2 and performed transcriptomic gene expression profiling (GEP) analysis, which included miRNAs, mRNAs, and lncRNAs, using microarray technology at 0, 12, 24, and 48 h after transfection. There were 38 miRNAs (33 upregulated and 5 downregulated), 2107 mRNAs (296 upregulated and 1811 downregulated), and 1190 lncRNAs (133 upregulated and 1057 downregulated) that were significantly dysregulated by p53. Some of the dysregulated molecules were confirmed by quantitative real-time polymerase chain reaction (qRT-PCR). Then, we integrated previously published miRNAs, mRNAs, and lncRNAs GEP datasets from NPC biopsies to investigate the expression of these p53 regulated molecules and found that 7 miRNAs, 218 mRNAs, and 101 lncRNAs regulated by p53 were also differentially expressed in NPC tissues. Finally, p53-regulated miRNA, mRNA, and lncRNA networks were constructed using bioinformatics methods. These miRNAs, mRNAs, and lncRNAs may participate in p53 downstream signaling pathways and play important roles in the carcinogenesis of NPC. Thorough investigations of their biological functions and regulating relationships will provide a novel view of the p53 signaling pathway, and the restoration of p53 functioning or its downstream gene regulating network is potentially of great value in treating NPC patients.
Appendix
Available only for authorised users
Literature
1.
Zeng Z, Huang H, Zhang W, Xiang B, Zhou M, et al. Nasopharyngeal carcinoma: advances in genomics and molecular genetics. Sci China Life Sci. 2011;54:966–75.CrossRefPubMed
2.
Xiong W, Zeng ZY, Xia JH, Xia K, Shen SR, et al. A susceptibility locus at chromosome 3p21 linked to familial nasopharyngeal carcinoma. Cancer Res. 2004;64:1972–4.CrossRefPubMed
3.
Zeng Z, Zhou Y, Zhang W, Li X, Xiong W, et al. Family-based association analysis validates chromosome 3p21 as a putative nasopharyngeal carcinoma susceptibility locus. Genet Med. 2006;8:156–60.CrossRefPubMed
4.
Stoker SD, van Diessen JN, de Boer JP, Karakullukcu B, Leemans CR, et al. Current treatment options for local residual nasopharyngeal carcinoma. Curr Treat Options Oncol. 2013;14:475–91.CrossRefPubMedPubMedCentral
5.
Liao Q, Zeng Z, Guo X, Li X, Wei F, et al. LPLUNC1 suppresses IL-6-induced nasopharyngeal carcinoma cell proliferation via inhibiting the Stat3 activation. Oncogene. 2014;33:2098–109.CrossRefPubMed
6.
Yang Y, Liao Q, Wei F, Li X, Zhang W, et al. LPLUNC1 inhibits nasopharyngeal carcinoma cell growth via down-regulation of the MAP kinase and cyclin D1/E2F pathways. PLoS One. 2013;8, e62869.CrossRefPubMedPubMedCentral
7.
Zeng Z, Zhou Y, Xiong W, Luo X, Zhang W, et al. Analysis of gene expression identifies candidate molecular markers in nasopharyngeal carcinoma using microdissection and cDNA microarray. J Cancer Res Clin Oncol. 2007;133:71–81.CrossRefPubMed
8.
Zeng ZY, Zhou YH, Zhang WL, Xiong W, Fan SQ, et al. Gene expression profiling of nasopharyngeal carcinoma reveals the abnormally regulated Wnt signaling pathway. Hum Pathol. 2007;38:120–33.CrossRefPubMed
9.
Zhang W, Fan S, Zou G, Shi L, Zeng Z, et al. Lactotransferrin could be a novel independent molecular prognosticator of nasopharyngeal carcinoma. Tumour Biol. 2015;36:675–83.CrossRefPubMed
10.
Zhang W, Zeng Z, Zhou Y, Xiong W, Fan S, et al. Identification of aberrant cell cycle regulation in Epstein-Barr virus-associated nasopharyngeal carcinoma by cDNA microarray and gene set enrichment analysis. Acta Biochim Biophys Sin (Shanghai). 2009;41:414–28.CrossRef
11.
Zhang W, Zeng Z, Fan S, Wang J, Yang J, et al. Evaluation of the prognostic value of TGF-beta superfamily type I receptor and TGF-beta type II receptor expression in nasopharyngeal carcinoma using high-throughput tissue microarrays. J Mol Histol. 2012;43:297–306.CrossRefPubMed
12.
Huang HB, Deng M, Zheng Y, Zhou YH, Zhang WL, et al. Innate immune protein lactotransferrin prevents initiation and arrests progression of nasopharyngeal carcinoma. Prog Biochem Biophys. 2013;40:319–24.
13.
Zeng Z, Fan S, Zhang X, Li S, Zhou M, et al. Epstein-Barr virus-encoded small RNA 1 (EBER-1) could predict good prognosis in nasopharyngeal carcinoma. Clin Transl Oncol. 2015;
14.
Xiong W, Wu X, Starnes S, Johnson SK, Haessler J, et al. An analysis of the clinical and biologic significance of TP53 loss and the identification of potential novel transcriptional targets of TP53 in multiple myeloma. Blood. 2008;112:4235–46.CrossRefPubMedPubMedCentral
15.
Gong ZJ, Huang HB, Xu K, Liang F, Li XL, et al. Advances in microRNAs and TP53 gene regulatory network. Prog Biochem Biophys. 2012;39:1133–44.CrossRef
16.
Li Y, Gordon MW, Xu-Monette ZY, Visco C, Tzankov A, et al. Single nucleotide variation in the TP53 3′ untranslated region in diffuse large B-cell lymphoma treated with rituximab-CHOP: a report from the International DLBCL Rituximab-CHOP Consortium Program. Blood. 2013;121:4529–40.CrossRefPubMedPubMedCentral
17.
Gong Z, Zhang S, Zeng Z, Wu H, Yang Q, et al. LOC401317, a p53-regulated long non-coding RNA, inhibits cell proliferation and induces apoptosis in the nasopharyngeal carcinoma cell line HNE2. PLoS One. 2014;9, e110674.CrossRefPubMedPubMedCentral
18.
19.
Siomi H, Siomi MC. Posttranscriptional regulation of microRNA biogenesis in animals. Mol Cell. 2010;38:323–32.CrossRefPubMed
20.
Rybak A, Fuchs H, Hadian K, Smirnova L, Wulczyn EA, et al. The let-7 target gene mouse lin-41 is a stem cell specific E3 ubiquitin ligase for the miRNA pathway protein Ago2. Nat Cell Biol. 2009;11:1411–20.CrossRefPubMed
21.
Fan YY, Long B, Liu F, Zhou LY, Wang K, et al. Establishment of cardiomyocyte-specific miR-30b transgenic mice and exploring the function of miR-30b. Prog Biochem Biophys. 2014;41:575–82.
22.
Pan YQ, Pan B, Liu XY, Li RZ, Yue JM. Dicer and its miRNAs are necessary gene and regulatory factors for differentiation and proliferation of vascular smooth muscle cell. Prog Biochem Biophys. 2014;41:1255–64.
23.
Wu G, Wang D, Huang Y, Han JD. The research progress of microRNAs in aging. Prog Biochem Biophys. 2014;41:273–87.
24.
Becker LE, Lu Z, Chen W, Xiong W, Kong M, et al. A systematic screen reveals microRNA clusters that significantly regulate four major signaling pathways. PLoS One. 2012;7, e48474.CrossRefPubMedPubMedCentral
25.
Ma X, Kumar M, Choudhury SN, Becker Buscaglia LE, Barker JR, et al. Loss of the miR-21 allele elevates the expression of its target genes and reduces tumorigenesis. Proc Natl Acad Sci U S A. 2011;108:10144–9.CrossRefPubMedPubMedCentral
26.
27.
Bo H, Gong Z, Zhang W, Li X, Zeng Y, et al. Upregulated long non-coding RNA AFAP1-AS1 expression is associated with progression and poor prognosis of nasopharyngeal carcinoma. Oncotarget. 2015;6(24):20404–18.
28.
Gong Z, Zhang S, Zhang W, Huang H, Li Q, et al. Long non-coding RNAs in cancer. Sci China Life Sci. 2012;55:1120–4.CrossRefPubMed
29.
Tang K, Wei F, Bo H, Huang HB, Zhang WL, et al. Cloning and functional characterization of a novel long non-coding RNA gene associated with hepatocellular carcinoma. Prog Biochem Biophys. 2014;41:153–62.
30.
Zhang W, Huang C, Gong Z, Zhao Y, Tang K, et al. Expression of LINC00312, a long intergenic non-coding RNA, is negatively correlated with tumor size but positively correlated with lymph node metastasis in nasopharyngeal carcinoma. J Mol Histol. 2013;44:545–54.CrossRefPubMed
31.
Li YW, Wang YM, Zhang XY, Xue D, Kuang B, et al. Progress of long noncoding RNA HOTAIR in human cancer. Prog Biochem Biophys. 2015;42:228–35.
32.
Bu D, Luo H, Jiao F, Fang S, Tan C, et al. Evolutionary annotation of conserved long non-coding RNAs in major mammalian species. Sci China Life Sci. 2015;
33.
Li J, Gao C, Wang Y, Ma W, Tu J, et al. A bioinformatics method for predicting long noncoding RNAs associated with vascular disease. Sci China Life Sci. 2014;57:852–7.CrossRefPubMed
34.
Chen YN, Xiong XD. Long noncoding RNA and epigenetic regulation. Prog Biochem Biophys. 2014;41:723–30.
35.
Cai B, Wu Z, Liao K, Zhang S. Long noncoding RNA HOTAIR can serve as a common molecular marker for lymph node metastasis: a meta-analysis. Tumour Biol. 2014;35:8445–50.CrossRefPubMed
36.
Deng K, Guo X, Wang H, Xia J. The lncRNA-MYC regulatory network in cancer. Tumour Biol. 2014;35:9497–503.CrossRefPubMed
37.
Dong Y, Liang G, Yuan B, Yang C, Gao R, et al. MALAT1 promotes the proliferation and metastasis of osteosarcoma cells by activating the PI3K/Akt pathway. Tumour Biol. 2015;36:1477–86.CrossRefPubMed
38.
Gan L, Xu M, Zhang Y, Zhang X, Guo W. Focusing on long noncoding RNA dysregulation in gastric cancer. Tumour Biol. 2015;36:129–41.CrossRefPubMed
39.
Gao Y, Chen G, Zeng Y, Zeng J, Lin M, et al. Invasion and metastasis-related long noncoding RNA expression profiles in hepatocellular carcinoma. Tumour Biol. 2015;
40.
Guo X, Xia J, Deng K. Long non-coding RNAs: emerging players in gastric cancer. Tumour Biol. 2014;35:10591–600.CrossRefPubMed
41.
Hajjari M, Khoshnevisan A, Shin YK. Molecular function and regulation of long non-coding RNAs: paradigms with potential roles in cancer. Tumour Biol. 2014;35:10645–63.CrossRefPubMed
42.
43.
Zeng Z, Fan S, Zhang X, Li S, Zhou M, et al. Epstein–Barr virus-encoded small RNA 1 (EBER-1) could predict 3 good prognosis in nasopharyngeal carcinoma. Clin Transl Oncol. 2015;
44.
Zeng Z, Bo H, Gong Z, Lian Y, Li X, et al. AFAP1-AS1, a long noncoding RNA upregulated in lung cancer and promotes invasion and metastasis. Tumour Biol. 2015;
45.
Wei F, Li XY, Li XL, Zhang WL, Liao QJ, et al. The effect and mechanism of PLUNC protein family against inflammation and carcinogenesis of nasopharyngeal carcinoma. Prog Biochem Biophys. 2014;41:24–31.
46.
Li Y, Lu H. Noncoding RNAs: “our turn” to join the p53 network. J Mol Cell Biol. 2014;6:179–80.CrossRefPubMed
47.
Gordon MW, Yan F, Zhong X, Mazumder PB, Xu-Monette ZY, et al. Regulation of p53-targeting microRNAs by polycyclic aromatic hydrocarbons: Implications in the etiology of multiple myeloma. Molecular carcinogenesis. 2014;
48.
Kumar M, Lu Z, Takwi AA, Chen W, Callander NS, et al. Negative regulation of the tumor suppressor p53 gene by microRNAs. Oncogene. 2011;30:843–53.CrossRefPubMed
49.
Ma X, Choudhury SN, Hua X, Dai Z, Li Y. Interaction of the oncogenic miR-21 microRNA and the p53 tumor suppressor pathway. Carcinogenesis. 2013;34:1216–23.CrossRefPubMedPubMedCentral
50.
51.
Lu Z, Liu M, Stribinskis V, Klinge CM, Ramos KS, et al. MicroRNA-21 promotes cell transformation by targeting the programmed cell death 4 gene. Oncogene. 2008;27:4373–9.CrossRefPubMed
52.
53.
Luo Z, Zhang L, Li Z, Li X, Li G, et al. An in silico analysis of dynamic changes in microRNA expression profiles in stepwise development of nasopharyngeal carcinoma. BMC Med Genomics. 2012;5:3.CrossRefPubMedPubMedCentral
54.
Sengupta S, den Boon JA, Chen IH, Newton MA, Dahl DB, et al. Genome-wide expression profiling reveals EBV-associated inhibition of MHC class I expression in nasopharyngeal carcinoma. Cancer Res. 2006;66:7999–8006.CrossRefPubMed
55.
Yang QQ, Deng YF. Genome-wide analysis of long non-coding RNA in primary nasopharyngeal carcinoma by microarray. Histopathology. 2015;66:1022–30.CrossRefPubMed
56.
Zeng Z, Huang H, Huang L, Sun M, Yan Q, et al. Regulation network and expression profiles of Epstein-Barr virus-encoded microRNAs and their potential target host genes in nasopharyngeal carcinomas. Sci China Life Sci. 2014;57:315–26.CrossRefPubMed
57.
Soares MR, Huber J, Rios AF, Ramos ES. Investigation of IGF2/ApaI and H19/RsaI polymorphisms in patients with cutaneous melanoma. Growth Horm IGF Res. 2010;20:295–7.CrossRefPubMed
58.
Huang HB, Liang F, Xiong W, Li XL, Zeng ZY, et al. Bioinformatics accelerates drug repositioning. Prog Biochem Biophys. 2012;39:35–44.CrossRef
59.
Liu N, Chen NY, Cui RX, Li WF, Li Y, et al. Prognostic value of a microRNA signature in nasopharyngeal carcinoma: a microRNA expression analysis. Lancet Oncol. 2012;13:633–41.CrossRefPubMed
60.
Sengupta S, den Boon JA, Chen IH, Newton MA, Stanhope SA, et al. MicroRNA 29c is down-regulated in nasopharyngeal carcinomas, up-regulating mRNAs encoding extracellular matrix proteins. Proc Natl Acad Sci U S A. 2008;105:5874–8.CrossRefPubMedPubMedCentral
61.
Chen HC, Chen GH, Chen YH, Liao WL, Liu CY, et al. MicroRNA deregulation and pathway alterations in nasopharyngeal carcinoma. Br J Cancer. 2009;100:1002–11.CrossRefPubMedPubMedCentral
62.
Li T, Chen JX, Fu XP, Yang S, Zhang Z, et al. MicroRNA expression profiling of nasopharyngeal carcinoma. Oncol Rep. 2011;25:1353–63.PubMed
63.
Lin J, Huo R, Xiao L, Zhu X, Xie J, et al. A novel p53/microRNA-22/Cyr61 axis in synovial cells regulates inflammation in rheumatoid arthritis. Arthritis Rheumatol. 2014;66:49–59.CrossRefPubMed
64.
Subramanian M, Francis P, Bilke S, Li XL, Hara T, et al. A mutant p53/let-7i-axis-regulated gene network drives cell migration, invasion and metastasis. Oncogene. 2015;34:1094–104.CrossRefPubMed
65.
Pan JJ, Zhang SW, Chen CB, Xiao SW, Sun Y, et al. Effect of recombinant adenovirus-p53 combined with radiotherapy on long-term prognosis of advanced nasopharyngeal carcinoma. J Clin Oncol Off J Am Soc Clin Oncol. 2009;27:799–804.CrossRef
66.
67.
Liu XF, Xia YF, Li MZ, Wang HM, He YX, et al. The effect of p21 antisense oligodeoxynucleotides on the radiosensitivity of nasopharyngeal carcinoma cells with normal p53 function. Cell Biol Int. 2006;30:283–7.CrossRefPubMed
68.
Nagai MA, Butugan O, Logullo A, Brentani MM. Expression of growth factors, proto-oncogenes, and p53 in nasopharyngeal angiofibromas. Laryngoscope. 1996;106:190–5.CrossRefPubMed
69.
70.
Xie C, Yuan J, Li H, Li M, Zhao G, et al. NONCODEv4: exploring the world of long non-coding RNA genes. Nucleic Acids Res. 2014;42:D98–103.CrossRefPubMed
71.
Huarte M, Guttman M, Feldser D, Garber M, Koziol MJ, et al. A large intergenic noncoding RNA induced by p53 mediates global gene repression in the p53 response. Cell. 2010;142:409–19.CrossRefPubMedPubMedCentral
72.
Hung T, Wang Y, Lin MF, Koegel AK, Kotake Y, et al. Extensive and coordinated transcription of noncoding RNAs within cell-cycle promoters. Nat Genet. 2011;43:621–9.CrossRefPubMedPubMedCentral
73.
Liu C, Chen Z, Fang J, Xu A, Zhang W, et al. H19-derived miR-675 contributes to bladder cancer cell proliferation by regulating p53 activation. Tumour Biol. 2015;
74.
Ma C, Nong K, Zhu H, Wang W, Huang X, et al. H19 promotes pancreatic cancer metastasis by derepressing let-7’s suppression on its target HMGA2-mediated EMT. Tumour Biol. 2014;35:9163–9.CrossRefPubMed
75.
76.
77.
Ergun S, Oztuzcu S. Oncocers: ceRNA-mediated cross-talk by sponging miRNAs in oncogenic pathways. Tumour Biol. 2015;36:3129–36.CrossRefPubMed
Metadata
Title
An integrative transcriptomic analysis reveals p53 regulated miRNA, mRNA, and lncRNA networks in nasopharyngeal carcinoma
Publication date
01-03-2016
Published in
Tumor Biology / Issue 3/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-4156-x

Other articles of this Issue 3/2016

Tumor Biology 3/2016 Go to the issue

Original Article

Anti-tumor activity of phenoxybenzamine hydrochloride on malignant glioma cells

Original Article

Do circulating long non-coding RNAs (lncRNAs) (LincRNA-p21, GAS 5, HOTAIR) predict the treatment response in patients with head and neck cancer treated with chemoradiotherapy?

Original Article

Synthetic Tet-inducible small hairpin RNAs targeting hTERT or Bcl-2 inhibit malignant phenotypes of bladder cancer T24 and 5637 cells

Original Article

Plasma miR-940 may serve as a novel biomarker for gastric cancer

OriginalPaper

Comparison of meta-analyses among elastosonography (ES) and positron emission tomography/computed tomography (PET/CT) imaging techniques in the application of prostate cancer diagnosis

Original Article

Roles of coinhibitory molecules B7-H3 and B7-H4 in esophageal squamous cell carcinoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits